LONDON (Alliance News) - EKF Diagnostics Holdings PLC said Thursday it has signed an exclusive agreement with US pharmaceutical company Oragenics Inc to manufacture Oragenics lantibiotic bulk drug substances in the US.
EKF Diagnostics estimate the partnership will generate multi-million dollars in revenue over the duration of the manufacturing agreement.
The Florida-based company is developing a pipeline of therapeutics to address the rise in drug-resistant infectious diseases as well as oral mucositis.
Under the agreement, EKF Diagnostics will manufacture compounds intended for preclinical and early stage clinical trials.
The manufacturing will take place in EKF's Elkhart enzyme production facility in Indiana, US.
Chief Executive Officer Julian Baines said: "We are delighted to partner with Oragenics in the development of lantibiotics. EKF has invested heavily in the Elkhart facility and we are now in a position to attract high quality pharmaceutical partners such as Oragenics."
Shares in EKF Diagnostics were up 2.3% Thursday at 31.39 pence each.
Ekf Diagnostics (EKF)